dc.creatorPera, Daniele Trevizan
dc.creatorPlanello, Jéssica Freitas
dc.creatorCancino, Juliana
dc.creatorPolikarpov, Igor
dc.creatorZucolotto, Valtencir
dc.creatorAvó, Lucimar Retto da Silva de
dc.creatorGermano, Carla Maria Ramos
dc.creatorMelo, Débora Gusmão
dc.date.accessioned2016-09-23T23:22:58Z
dc.date.accessioned2018-07-04T17:09:08Z
dc.date.available2016-09-23T23:22:58Z
dc.date.available2018-07-04T17:09:08Z
dc.date.created2016-09-23T23:22:58Z
dc.date.issued2014-08
dc.identifierJournal of Nanotechnology in Engineering and Medicine, New York : American Society of Mechanical Engineers - ASME, v. 5, n. 3, p. 031001-1-031001-8, Aug. 2014
dc.identifier1949-2944
dc.identifierhttp://www.producao.usp.br/handle/BDPI/50891
dc.identifier10.1115/1.4028695
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1645352
dc.description.abstractWe aimed to investigate 3,5,3′-triiodothyroacetic acid (TRIAC) effects on intact and atrophic skin induced by glucocorticoids (GCs) in rats and the effects induced by nanoencapsulation. The effects of TRIAC and nanoencapsulated TRIAC were evaluated on intact and atrophic skin in TRIAC experiment and nanoencapsulated TRIAC experiment, respectively. Both experiments had two phases: phase I, cutaneous atrophy was induced; phase II, TRIAC or nanoencapsulated TRIAC was administrated. Our results showed that topical use of TRIAC with or without nanoencapsulation was able to reverse cutaneous atrophy. Nanoencapsulated TRIAC showed less systemic changes than TRIAC; therefore, it is possibly a safer drug for topical administration.
dc.languageeng
dc.publisherAmerican Society of Mechanical Engineers - ASME
dc.publisherNew York
dc.relationJournal of Nanotechnology in Engineering and Medicine
dc.rightsCopyright ASME
dc.rightsrestrictedAccess
dc.titleEffects of 3,5,3′-triiodothyroacetic acid, nanoencapsulated or not, on intact and atrophic skin in rats
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución